|
1
|
Carnero A, Blanco-Aparicio C, Renner O,
Link W and Leal J: The PTEN/PI3K/AKT signalling pathway in cancer,
therapeutic implications. Curr Cancer Drug Targets. 8:187–198.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sun Z, Huang C, He J, Lamb KL, Kang X, Gu
T, Shen WH and Yin Y: PTEN C-terminal deletion causes genomic
instability and tumor development. Cell Rep. 6:844–854. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Murphy SJ, Karnes RJ, Kosari F, Castellar
BE, Kipp BR, Johnson SH, Terra S, Harris FR, Halling GC, Klein JL,
et al: Integrated analysis of the genomic instability of PTEN in
clinically insignificant and significant prostate cancer. Mod
Pathol. 29:143–156. 2016. View Article : Google Scholar
|
|
4
|
Molinari F and Frattini M: Functions and
regulation of the PTEN gene in colorectal cancer. Front Oncol.
3:3262014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Berger AH, Knudson AG and Pandolfi PP: A
continuum model for tumour suppression. Nature. 476:163–169. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Alimonti A, Carracedo A, Clohessy JG,
Trotman LC, Nardella C, Egia A, Salmena L, Sampieri K, Haveman WJ,
Brogi E, et al: Subtle variations in Pten dose determine cancer
susceptibility. Nat Genet. 42:454–458. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Trotman LC, Niki M, Dotan ZA, Koutcher JA,
Di Cristofano A, Xiao A, Khoo AS, Roy-Burman P, Greenberg NM, Van
Dyke T, et al: Pten dose dictates cancer progression in the
prostate. PLoS Biol. 1:E592003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Garofalo M, Di Leva G, Romano G, Nuovo G,
Suh SS, Ngankeu A, Taccioli C, Pichiorri F, Alder H, Secchiero P,
et al: miR-221&222 regulate TRAIL resistance and enhance
tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell.
16:498–509. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Huse JT, Brennan C, Hambardzumyan D, Wee
B, Pena J, Rouhanifard SH, Sohn-Lee C, le Sage C, Agami R, Tuschl T
and Holland EC: The PTEN-regulating microRNA miR-26a is amplified
in high-grade glioma and facilitates gliomagenesis in vivo. Genes
Dev. 23:1327–1337. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tabach Y, Billi AC, Hayes GD, Newman MA,
Zuk O, Gabel H, Kamath R, Yacoby K, Chapman B, Garcia SM, et al:
Identification of small RNA pathway genes using patterns of
phylogenetic conservation and divergence. Nature. 493:694–698.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mullany LE, Herrick JS, Wolff RK, Stevens
JR, Samowitz W and Slattery ML: MicroRNA-transcription factor
interactions and their combined effect on target gene expression in
colon cancer cases. Genes, Chromosom Cancer. 57:192–202. 2018.
View Article : Google Scholar
|
|
12
|
Volinia S, Calin GA, Liu CG, Ambs S,
Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et
al: A microRNA expression signature of human solid tumors defines
cancer gene targets. Proc Natl Acad Sci USA. 103:2257–2261. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Frankel LB, Christoffersen NR, Jacobsen A,
Lindow M, Krogh A and Lund AH: Programmed cell death 4 (PDCD4) is
an important functional target of the microRNA miR-21 in breast
cancer cells. J Biol Chem. 283:1026–1033. 2008. View Article : Google Scholar
|
|
14
|
Zhu S, Si ML, Wu H and Mo YY: MicroRNA-21
targets the tumor suppressor gene tropomyosin 1 (TPM1). J Biol
Chem. 282:14328–14336. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chan JA, Krichevsky AM and Kosik KS:
MicroRNA-21 Is an antiapoptotic factor in human glioblastoma cells.
Cancer Res. 65:6029–6033. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tay Y, Rinn J and Pandolfi PP: The
multilayered complexity of ceRNA crosstalk and competition. Nature.
505:344–352. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zarringhalam K, Tay Y, Kulkarni P, Bester
AC, Pandolfi PP and Kulkarni RV: Identification of competing
endogenous RNAs of the tumor suppressor gene PTEN: A probabilistic
approach. Sci Rep. 7:77552017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Poliseno L and Pandolfi PP: PTEN ceRNA
networks in human cancer. Methods. 77-78:41–50. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Karreth FA, Tay Y, Perna D, Ala U, Tan SM,
Rust AG, DeNicola G, Webster KA, Weiss D, Perez-Mancera PA, et al:
In vivo identification of tumor-suppressive PTEN ceRNAs in an
oncogenic BRAF-induced mouse model of melanoma. Cell. 147:382–395.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Marone M, Mozzetti S, De Ritis D, Pierelli
L and Scambia G: Semiquantitative RT-PCR analysis to assess the
expression levels of multiple transcripts from the same sample.
Biol Proced Online. 3:19–25. 2001. View
Article : Google Scholar
|
|
21
|
Langlois MJ, Bergeron S, Bernatchez G,
Boudreau F, Saucier C, Perreault N, Carrier JC and Rivard N: The
PTEN phosphatase controls intestinal epithelial cell polarity and
barrier function: Role in colorectal cancer progression. PLoS One.
5:e157422010. View Article : Google Scholar
|
|
22
|
Rhee I, Bachman KE, Park BH, Jair KW, Yen
RW, Schuebel KE, Cui H, Feinberg AP, Lengauer C, Kinzler KW, et al:
DNMT1 and DNMT3b cooperate to silence genes in human cancer cells.
Nature. 416:552–556. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Uribe-Lewis S, Stark R, Carroll T, Dunning
MJ, Bachman M, Ito Y, Stojic L, Halim S, Vowler SL, Lynch AG, et
al: 5-hydroxy-methylcytosine marks promoters in colon that resist
DNA hypermethylation in cancer. Genome Biol. 16:692015. View Article : Google Scholar
|
|
24
|
García JM, Silva J, Peña C, Garcia V,
Rodríguez R, Cruz MA, Cantos B, Provencio M, España P and Bonilla
F: Promoter methylation of the PTEN gene is a common molecular
change in breast cancer. Genes Chromosom Cancer. 41:117–124. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Alvarez-Nuñez F, Bussaglia E, Mauricio D,
Ybarra J, Vilar M, Lerma E, de Leiva A and Matias-Guiu X; Thyroid
Neoplasia Study Group: PTEN promoter methylation in sporadic
thyroid carcinomas. Thyroid. 16:17–23. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lu J, Jeong H, Kong N, Yang Y, Carroll J,
Luo HR, Silberstein LE, Yupoma and Chai L: Stem cell factor SALL4
represses the transcriptions of PTEN and SALL1 through an
epigenetic repressor complex. PLoS One. 4:e55772009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hettinger K, Vikhanskaya F, Poh MK, Lee
MK, de Belle I, Zhang JT, Reddy SA and Sabapathy K: c-Jun promotes
cellular survival by suppression of PTEN. Cell Death Differ.
14:218–229. 2007. View Article : Google Scholar
|
|
28
|
Vasudevan KM, Gurumurthy S and Rangnekar
VM: Suppression of PTEN expression by NF-kappa B prevents
apoptosis. Mol Cell Biol. 24:1007–1021. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Meng F, Henson R, Wehbe-Janek H, Ghoshal
K, Jacob ST and Patel T: MicroRNA-21 regulates expression of the
PTEN tumor suppressor gene in human hepatocellular cancer.
Gastroenterology. 133:647–658. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tay Y, Kats L, Salmena L, Weiss D, Tan SM,
Ala U, Karreth F, Poliseno L, Provero P, Di Cunto F, et al:
Coding-independent regulation of the tumor suppressor PTEN by
competing endogenous mRNAs. Cell. 147:344–357. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Poliseno L, Salmena L, Zhang J, Carver B,
Haveman WJ and Pandolfi PP: A coding-independent function of gene
and pseudogene mRNAs regulates tumour biology. Nature.
465:1033–1038. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Salmena L, Poliseno L, Tay Y, Kats L and
Pandolfi PP: A ceRNA Hypothesis: The rosetta stone of a hidden RNA
language? Cell. 146:353–358. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yamakuchi M, Lotterman CD, Bao C, Hruban
RH, Karim B, Mendell JT, Huso D and Lowenstein CJ: P53-induced
microRNA-107 inhibits HIF-1 and tumor angiogenesis. Proc Natl Acad
Sci USA. 107:6334–6339. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang B, Hsu SH, Wang X, Kutay H, Bid HK,
Yu J, Ganju RK, Jacob ST, Yuneva M and Ghoshal K: Reciprocal
regulation of microRNA-122 and c-Myc in hepatocellular cancer: Role
of E2F1 and transcription factor dimerization partner 2.
Hepatology. 59:555–566. 2014. View Article : Google Scholar
|
|
35
|
Sumazin P, Yang X, Chiu HS, Chung WJ, Iyer
A, Llobet-Navas D, Rajbhandari P, Bansal M, Guarnieri P, Silva J
and Califano A: An Extensive MicroRNA-mediated network of RNA-RNA
interactions regulates established oncogenic pathways in
glio-blastoma. Cell. 147:370–381. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Jeyapalan Z, Deng Z, Shatseva T, Fang L,
He C and Yang BB: Expression of CD44 3'-untranslated region
regulates endogenous microRNA functions in tumorigenesis and
angiogenesis. Nucleic Acids Res. 39:3026–3041. 2011. View Article : Google Scholar
|
|
37
|
Rutnam ZJ, Du WW, Yang W, Yang X and Yang
BB: The pseu-dogene TUSC2P promotes TUSC2 function by binding
multiple microRNAs. Nat Commun. 5:29142014. View Article : Google Scholar
|
|
38
|
Karreth FA, Reschke M, Ruocco A, Ng C,
Chapuy B, Léopold V, Sjoberg M, Keane TM, Verma A, Ala U, et al:
The BRAF pseu-dogene functions as a competitive endogenous RNA and
induces lymphoma in vivo. Cell. 161:319–332. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wang L, Guo ZY, Zhang R, Xin B, Chen R,
Zhao J, Wang T, Wen WH, Jia LT, Yao LB and Yang AG: Pseudogene
OCT4-pg4 functions as a natural micro RNA sponge to regulate OCT4
expression by competing for miR-145 in hepatocellular carcinoma.
Carcinogenesis. 34:1773–1781. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Sanchez-Mejias A and Tay Y: Competing
endogenous RNA networks: Tying the essential knots for cancer
biology and therapeutics. J Hematol Oncol. 8:302015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ergun S and Oztuzcu S: Oncocers:
ceRNA-mediated cross-talk by sponging miRNAs in oncogenic pathways.
Tumor Biol. 36:3129–3136. 2015. View Article : Google Scholar
|
|
42
|
Park SM, Gaur AB, Lengyel E and Peter ME:
The miR-200 family determines the epithelial phenotype of cancer
cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes
Dev. 22:894–907. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Xu J, Li Y, Lu J, Pan T, Ding N, Wang Z,
Shao T, Zhang J, Wang L and Li X: The mRNA related ceRNA-ceRNA
landscape and significance across 20 major cancer types. Nucleic
Acids Res. 43:8169–8182. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Chen L, Zheng J, Zhang Y, Yang L, Wang J,
Ni J, Cui D, Yu C and Cai Z: Tumor-specific Expression of
MicroRNA-26a suppresses human hepatocellular carcinoma growth via
cyclin-dependent and -independent pathways. Mol Ther. 19:1521–1528.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Sandhu R, Rivenbark AG and Coleman WB:
Enhancement of chemotherapeutic efficacy in hypermethylator breast
cancer cells through targeted and pharmacologic inhibition of
DNMT3b. Breast Cancer Res Treat. 131:385–399. 2012. View Article : Google Scholar
|
|
46
|
Noack F and Calegari F: MicroRNAs meet
epigenetics to make for better brains. EMBO Rep. 15:1224–1225.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Garcia DM, Baek D, Shin C, Bell GW,
Grimson A and Bartel DP: Weak seed-pairing stability and high
target-site abundance decrease the proficiency of lsy-6 and other
miRNAs. Nat Struct Mol Biol. 18:1139–1146. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Friedman RC, Farh KK, Burge CB and Bartel
DP: Most mammalian mRNAs are conserved targets of microRNAs. Genome
Res. 19:92–105. 2009. View Article : Google Scholar :
|
